DrugBiological
Botensilimab clinical trials
Also written AGEN1181.
Keep track of what changes. Save the botensilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2025 (8); 2 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 26
City of Hope Medical Center (4) · Agenus Inc. (4) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (2) · Northwestern University (1) · Immune Oncology Research Institute (1) · University of Colorado, Denver (1) · Nicholas DeVito, MD (1)
Often tested with
Tested in the same studies.
Balstilimab (27) · Doxorubicin (2) · Bevacizumab (2) · Allogeneic Invariant Natural Killer T-cells agenT-797 (2) · Paclitaxel (2) · Liposomal doxorubicin (1) · Regorafenib (1) · Ramucirumab (1)
Studies
Open first, then newest update. How each study uses botensilimab is read from its arms, and is right about nine times in ten.
Testing it · 30
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07516366Written as Botensilimab
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingPhase 2City of Hope Medical CenterNCT07595874Written as Botensilimab
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07551596Written as Botensilimab
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07227636Written as Botensilimab
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Botensilimab
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingPhase 2Benjamin SpielerNCT06843551Written as Botensilimab
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT07735624Written as Botensilimab
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingPhase 2Darren Sigal, MDNCT07550088Written as Botensilimab (BOT)
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as Botensilimab
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingPhase 2City of Hope Medical CenterNCT06780787Written as Botensilimab
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as Botensilimab
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingEarly Phase 1Northwell HealthNCT07193862Written as Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06843434Written as Botensilimab
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingEarly Phase 1Massachusetts General HospitalNCT07128355Written as Botensilimab
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingPhase 1University of Southern CaliforniaNCT06336902Written as Botensilimab
- Combination Immunotherapy in Colorectal CancerCompletedPhase 2Weill Medical College of Cornell UniversityNCT05571293Written as Botensilimab
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Northwestern UniversityNCT05864534Written as Botensilimab
- FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingPhase 1/2City of Hope Medical CenterNCT05627635Written as Botensilimab
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingPhase 1/2City of Hope Medical CenterNCT05672316Written as Botensilimab
- Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal AdenocarcinomaTerminatedPhase 3Canadian Cancer Trials GroupNCT07152821Written as Botensilimab
See all 30 studies that test botensilimab →
Given in every arm · 7 — botensilimab is usual care beside what is tested
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06300463Written as Botensilimab
- A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.Not yet recruitingPhase 2Nelum CorpNCT07578337Written as Botensilimab
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsRecruitingPhase 2/3The Netherlands Cancer InstituteNCT06279130Written as botensilimab
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedPhase 2Agenus Inc.NCT05529316Written as Botensilimab
- AGEN1423 and Botensilimab w/ or w/o Chemo in PDACActive, not recruitingPhase 2Bruno BockornyNCT05632328Written as Botensilimab
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingPhase 1Agenus Inc.NCT03860272Written as Botensilimab
- Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerWithdrawnPhase 2City of Hope Medical CenterNCT06575725Written as Botensilimab
Codes
What other systems call botensilimab · ClinicalTrials.gg INT014370
- UNII (FDA) 1Z5YC3ME5NBOTENSILIMABOne source FDA
- NCI Thesaurus C158557BotensilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1Z5YC3ME5N | BOTENSILIMAB | One source FDA |
| NCI Thesaurus | C158557 | Botensilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.